These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 34512203)

  • 1. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
    Diao B; Yang P
    Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and bioinformatics analysis of the relationship between LAMA3 DNA methylation expression and platinum resistance and prognosis in epithelial ovarian cancer].
    Chen CX; Zhang YL; Huang YZ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2024 Jun; 59(6):454-464. PubMed ID: 38951081
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of LAMA4 on Prognosis and Its Correlation with Immune Infiltration in Gastric Cancer.
    Wang M; Li C; Liu Y; Wang Z
    Biomed Res Int; 2021; 2021():6428873. PubMed ID: 34414238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
    Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
    J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
    Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
    [No Abstract]   [Full Text] [Related]  

  • 7. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
    Li W; Huang L; Qi N; Zhang Q; Qin Z
    BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel biomarker, MRPS12 functions as a potential oncogene in ovarian cancer and is a promising prognostic candidate.
    Qiu X; Guo D; Du J; Bai Y; Wang F
    Medicine (Baltimore); 2021 Feb; 100(8):e24898. PubMed ID: 33663122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Analysis of Prognosis and Immune Infiltration of Ovarian Cancer Based on Homeobox D Genes.
    Chen B; Gao C; Wang H; Sun J; Han Z
    Comput Math Methods Med; 2022; 2022():3268386. PubMed ID: 36213580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Prognostic Value of MEX3A and Its Relationship with Immune Infiltrates in Ovarian Cancer.
    Zhang P; Su T; Zhang S
    J Immunol Res; 2021; 2021():5574176. PubMed ID: 34189143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer.
    Xu H; Zou R; Li F; Liu J; Luan N; Wang S; Zhu L
    Cancer Med; 2021 Jun; 10(11):3655-3673. PubMed ID: 33934540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
    Huang C; Cui H; Lang X; Zhao F
    J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the KRT7 Biomarker in Immune Infiltration and Paclitaxel Resistance in Ovarian.
    Wang S; Li H; Li M; Liu X; Yu S; Huang H; Wang X
    Altern Ther Health Med; 2023 Jul; 29(5):132-140. PubMed ID: 37023314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of the lysyl oxidase family in ovarian cancer.
    Ye M; Zhou J; Gao Y; Pan S; Zhu X
    J Clin Lab Anal; 2020 Dec; 34(12):e23538. PubMed ID: 33058284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor of DNA-binding family regulates the prognosis of ovarian cancer.
    Zhou Q; Mei YD; Yang HJ; Tao YL
    Future Oncol; 2021 May; 17(15):1889-1906. PubMed ID: 33728938
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
    Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
    Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Epithelial Splicing Regulatory Protein 1 in Metastatic Lesions of Serous Ovarian Carcinoma Correlates with Poor Patient Prognosis.
    Lu X; Li R; Wang X; Guo Q; Wang L; Zhou X
    Cancer Biother Radiopharm; 2022 Nov; 37(9):850-861. PubMed ID: 34495766
    [No Abstract]   [Full Text] [Related]  

  • 19. Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer.
    Li H; Liu C; Lu Z; Chen L; Wang J; Li Y; Ma H
    Biomed Pharmacother; 2017 Apr; 88():529-534. PubMed ID: 28129625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [DNA methylation in the promoter regions of the laminin family genes in normal and breast carcinoma tissues].
    Simonova OA; Kuznetsova EB; Poddubskaya EV; Kekeeva TV; Kerimov RA; Trotsenko ID; Tanas AS; Rudenko VV; Alekseeva EA; Zaletayev DV; Strelnikov VV
    Mol Biol (Mosk); 2015; 49(4):667-77. PubMed ID: 26299867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.